MediWound Ltd. Stock News

Full-Year 2021 Total Revenues of $23.8 Million; Product Revenues Up 46%

Full-Year 2021 Total Revenues of $23.8 Million; Product Revenues Up 46%

MediWound (MDWD) delivered earnings and revenue surprises of 6.25% and 2.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ: TGA ) is estimated to report earnings for its fourth quarter. • Ikena Oncology (NASDAQ: IKNA ) is projected to report earnings for its fourth quarter. • RF Industries (NASDAQ: RFIL ) is likely to report quarterly earnings at $0.04 per share on revenue of $15.84 million. • Destination XL Group (NASDAQ: DXLG ) is estimated to report quarterly earnings at $0.13 per share on revenue of $131.88 million. • Liquidia (NASDAQ: LQDA ) is projected to report quarterly loss at $0.11 per share on revenue of $3.05 million. • IMV (NASDAQ: IMV ) is projected to report quarterly loss at $0.13 per share on revenue of $50.00 thousand. • Redhill Biopharma (NASDAQ: RDHL ) is likely to report quarterly loss at $0.33 per share on revenue of $24.08 million. • Designer Brands (NYSE: DBI ) is likely to report quarterly earnings at $0.16 per share on revenue of $839.61 million. • Kirkland''s (NASDAQ: KIRK ) is expected to report quarterly earnings at $0.

Catalyst (CPRX) delivered earnings and revenue surprises of -25% and 0.37%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

MediWound (NASDAQ:MDWD) is scheduled to announce Q4 earnings results on Thursday, March 17th, before market open.The consensus EPS Estimate is -$0.15 (-150.0% Y/Y) and the consensus…

Dipexium Pharmaceuticals, Inc. (PLXP) delivered earnings and revenue surprises of -5.80% and 17.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for

YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, b

YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair a

YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the fourth quarter and year ended December 31, 2021 on Thursday, March 17 2022.

YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and

MediWound (MDWD) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a t

DBV Technologies DBVT +16%. EyePoint Pharmaceuticals (EYPT) +14%. NuCana (NCNA) -54%. MediWound (MDWD) -15%.

MediWound (MDWD) plunged 17.9% premarket after pricing its underwritten public offering of 5.2M shares at a public offering price of $1.92/share.Gross proceeds are expected to…

MediWound (MDWD), a commercial-stage pharmaceutical company focused on tissue repair and regeneration, has lost ~29% in the post-market Wednesday after announcing a proposed…